NASDAQ : KDNY

Chinook Therapeutics, Inc.

$40.39 USD

$0.09 (0.22%)

Volume
3.28M
Average Volume
2.05M
Market Capitalization
$2.71B
P/E Ratio
-14.07
Dividend Yield
0.00%
Price Target
$30.00
Year High
$40.51
Year Low
$18.34
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$7.59
Company Overview

NASDAQ

Eric L. Dobmeier

Biotechnology

Healthcare

KDNY

214

US

USD

https://www.chinooktx.com

206 485 7241

16961L106

0001435049

Liquidity Metrics

0.09

7.59

7.59

2.27

0.00

Sales & Valuation

$6.13M

441.93

5.88

-22.73

-1.85

Profitability

-$2.87

-$184.62M

-3012.65%

-2941.81%

-41.23%

-32.16%

P/E Metrics

-14.07

0.21

0.21

Analyst Price Target & Rating

$30.00

$30.00

$30.00

N/A

0/5

11 Analysts

34.63%

Financial Health Scores

9.69

3/9

$252.94M

$488.81M

$131.77M

-$252.86M

Key Metrics (TTM)

$2.63B

429.53

-16.03

7.59

-41.23%

-35.04%

-7.10%

-4.40%

-2002 days

Company Executives
Name Title
Jodi Jamieson Senior Vice President of HR
Sukhi Thethy Senior Vice President of Fin. & Accounting
Noopur Batsha Liffick Senior Vice President of Investor Relations & Corporation Communications
Poll Results

No votes yet today — be the first to share your view!

About Chinook Therapeutics, Inc. (NASDAQ:KDNY) Stock

Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. Th ... e firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.

Frequently Asked Questions

What is the current Chinook Therapeutics, Inc. (KDNY) stock price?

Chinook Therapeutics, Inc.(NASDAQ:KDNY) stock price is $40.39 in the last trading session. During the trading session, KDNY stock reached the peak price of $40.51 while $18.34 was the lowest point it dropped to. The percentage change in KDNY stock occurred in the recent session was 0.22% while the dollar amount for the price change in KDNY stock was $0.09.

KDNY's industry and sector of operation?

The NASDAQ listed KDNY is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of KDNY?

Jodi Jamieson | Senior Vice President of HR
Sukhi Thethy | Senior Vice President of Fin. & Accounting
Noopur Batsha Liffick | Senior Vice President of Investor Relations & Corporation Communications
|
|

How many employees does KDNY have?

Number of KDNY employees currently stands at 214. KDNY operates from 400 Fairview Avenue North, Seattle, WA 98109, US.

Link for KDNY official website?

Official Website of KDNY is: https://www.chinooktx.com

How do I contact KDNY?

KDNY could be contacted at phone #206 485 7241 and can also be accessed through its website. KDNY operates from 400 Fairview Avenue North, Seattle, WA 98109, US.

How many shares of KDNY are traded daily?

The average number of KDNY shares traded daily for last 3 months was 2.05M.

What is the market cap of KDNY currently?

The market value of KDNY currently stands at $2.71B with its latest stock price at $40.39